Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria

77Citations
Citations of this article
50Readers
Mendeley users who have this article in their library.

Abstract

Background: Elevated fibroblast growth factor 21 (FGF21) levels have been suggested, from crosssectional studies, as an indicator of subclinical diabetic nephropathy. We investigated whether serum FGF21 was predictive of the development of diabetic nephropathy. Method: Baseline serum FGF21 levels were measured in 1136 Chinese type 2 diabetic subjects recruited from the Hong Kong West Diabetes Registry. The role of serum FGF21 in predicting decline in estimated glomerular filtration rate (eGFR) over a median follow-up of 4 years was analyzed using Cox regression analysis. Results: At baseline, serum FGF21 levels increased progressively with eGFR category (P for trend

Cite

CITATION STYLE

APA

Lee, C. H., Hui, E. Y. L., Woo, Y. C., Yeung, C. Y., Chow, W. S., Yuen, M. M. A., … Lam, K. S. L. (2015). Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria. Journal of Clinical Endocrinology and Metabolism, 100(4), 1368–1375. https://doi.org/10.1210/jc.2014-3465

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free